Stock Events

Stock Events

Protalix BioTherapeutics 

$2.6
46
+$0.26+11.11% Today

Statistics

Day High
2.63
Day Low
2.35
52W High
3.1
52W Low
1.32
Volume
1,664,963
Avg. Volume
701,531
Mkt Cap
209.09M
P/E Ratio
26.33
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.05
0
0.05
0.1
Expected EPS
0.04
Actual EPS
N/A

Financials

5.49%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
106.8MRevenue
5.86MNet Income

Analyst Ratings

$12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PLX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes in the biopharmaceutical space, developing drugs that could directly compete with Protalix's treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on novel therapies in various areas, including those that Protalix targets, making them direct competitors.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences operates in the biopharmaceutical field, producing competitive drugs in the same therapeutic areas as Protalix.
Biogen
BIIB
Mkt Cap22.63B
Biogen develops therapies for diseases with unmet medical needs, potentially competing with Protalix's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, some of which may overlap with Protalix's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops biologic medicines, including for conditions that Protalix is also targeting.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a global healthcare company with products that could compete in the therapeutic areas Protalix is involved in.
Sanofi
SNY
Mkt Cap124.45B
Sanofi develops a wide range of medicines, including those in areas where Protalix is seeking to make an impact.

About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Show more...
CEO
Mr. Dror Bashan
Employees
213
Country
US
ISIN
US74365A3095

Listings

XASE
US
PLX
F
DE
PBDA.F
BOATS
BOATS
PLX.BOATS

0 Comments

Share your thoughts

FAQ

What is Protalix BioTherapeutics stock price today?▼
The current price of PLX is $2.6 USD — it has increased by +11.11% in the past 24 hours. Watch Protalix BioTherapeutics stock price performance more closely on the chart.
What is Protalix BioTherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protalix BioTherapeutics stocks are traded under the ticker PLX.
Is Protalix BioTherapeutics stock price growing?▼
PLX stock has risen by +25.24% compared to the previous week, the month change is a +48.28% rise, over the last year Protalix BioTherapeutics has showed a +6.17% increase.
What is Protalix BioTherapeutics market cap?▼
Today Protalix BioTherapeutics has the market capitalization of 209.09M
When is the next Protalix BioTherapeutics earnings date?▼
Protalix BioTherapeutics is going to release the next earnings report on March 12, 2026.
What were Protalix BioTherapeutics earnings last quarter?▼
PLX earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.06 USD resulting in a -45.45% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protalix BioTherapeutics revenue for the last year?▼
Protalix BioTherapeutics revenue for the last year amounts to 106.8M USD.
What is Protalix BioTherapeutics net income for the last year?▼
PLX net income for the last year is 5.86M USD.
How many employees does Protalix BioTherapeutics have?▼
As of February 02, 2026, the company has 213 employees.
In which sector is Protalix BioTherapeutics located?▼
Protalix BioTherapeutics operates in the Health Care sector.
When did Protalix BioTherapeutics complete a stock split?▼
The last stock split for Protalix BioTherapeutics was on December 20, 2019 with a ratio of 1:10.
Where is Protalix BioTherapeutics headquartered?▼
Protalix BioTherapeutics is headquartered in Hackensack, US.